Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Illidge

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 8, 2014
Emerging opportunities for the combination of molecularly targeted drugs with radiotherapyE J Searle, T M Illidge, I J Stratford
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 7, 2003
Cervical neuropathy following mantle radiotherapyV J McFarlane, G P Clein, J Cole, et al.
Cell Biology International|August 31, 2000
Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damageT M Illidge, M S Cragg, B Fringes, et al.
Cell Biology International|August 31, 2000
Release of mitotic descendants by giant cells from irradiated Burkitt's lymphoma cell lineJ A Erenpreisa, M S Cragg, B Fringes, et al.
The British Journal of Radiology|September 14, 2012
Radiotherapy physics research in the UK: challenges and proposed solutionsR I Mackay, N G Burnet, S Green, et al.
Blood|June 25, 1999
The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphomaT M Illidge, M S Cragg, H M McBride, et al.
Leukemia|July 29, 2017
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2018
Recommendations for the clinical management of the elderly patient with malignant lymphomaL Specht, B Aleman, H Eich, et al.
Leukemia|November 29, 2016
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Journal of Immunological Methods|June 16, 2010
Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjectsG Hampson, T H Ward, J Cummings, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 8, 2014
Emerging opportunities for the combination of molecularly targeted drugs with radiotherapyE J Searle, T M Illidge, I J Stratford
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 7, 2003
Cervical neuropathy following mantle radiotherapyV J McFarlane, G P Clein, J Cole, et al.
Cell Biology International|August 31, 2000
Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damageT M Illidge, M S Cragg, B Fringes, et al.
Cell Biology International|August 31, 2000
Release of mitotic descendants by giant cells from irradiated Burkitt's lymphoma cell lineJ A Erenpreisa, M S Cragg, B Fringes, et al.
The British Journal of Radiology|September 14, 2012
Radiotherapy physics research in the UK: challenges and proposed solutionsR I Mackay, N G Burnet, S Green, et al.
Blood|June 25, 1999
The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphomaT M Illidge, M S Cragg, H M McBride, et al.
Leukemia|July 29, 2017
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2018
Recommendations for the clinical management of the elderly patient with malignant lymphomaL Specht, B Aleman, H Eich, et al.
Leukemia|November 29, 2016
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cellsE J Cheadle, G Lipowska-Bhalla, S J Dovedi, et al.
Journal of Immunological Methods|June 16, 2010
Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjectsG Hampson, T H Ward, J Cummings, et al.
Pageof 3